HIF1A and head and neck squamous cell carcinoma: The benefits of adding Nimotuzumab to combination therapy with cisplatin and radiotherapy have been reported in some HNSCC patients [146], and high HIF1α (hypoxia-inducible factor 1-alpha) expression may indicate likely benefit for such treatments [145].